Literature DB >> 26816887

Fosfomycin: An Alternative Therapy for the Treatment of UTI Amidst Escalating Antimicrobial Resistance.

Ekadashi Rajni Sabharwal1, Rajni Sharma2.   

Abstract

INTRODUCTION: Urinary tract infections (UTIs) are the most commonly encountered infectious diseases. The current study was undertaken with a dual purpose, to provide an insight into the current scenario of the microorganisms causing UTI, their antimicrobial sensitivity patterns and also try and evaluate the activity of fosfomycin against E. coli, both ESBL producers as well as non-producers.
MATERIALS AND METHODS: The study was conducted prospectively in the Department of Microbiology of a tertiary care hospital from January to June 2014. A total of 358 isolates from the urinary samples of the patients with a diagnosis of urinary tract infection were included in the study. Antibiotic sensitivity testing and extended spectrum beta lactamase (ESBL) production testing was done as per CLSI guidelines.
RESULTS: These represented 297 (82.9%) gram-negative isolates and 61 (17%) gram-positive isolates. The 297 gram-negative isolates represented 265 (89.2%) members of the Enterobacteriaceae, 185 (69.8%) of which were Escherichia coli, 66 (24.9%) Klebsiella spp. and 14 (5.28%) Proteus spp. Non-fermentative Pseudomonas spp were isolated from 8.9% cases. Amongst the Gram negative isolates tested, 78 (21.8%) formed extended spectrum beta-lactamases. Of the total 358 isolates tested, 338 (94.4%) were found to be susceptible to fosfomycin.
CONCLUSION: Fosfomycin showed good activity against both ESBL-producing and ESBL-negative E. coli isolates. The main finding of our study is that fosfomycin exhibits excellent antimicrobial activity even against the isolates with relatively high levels of antimicrobial resistance and hence can be a useful drug in our armamentarium.

Entities:  

Keywords:  Antimicrobial agents; Antimicrobial sensitivity; Extended spectrum beta lactamase (ESBL)

Year:  2015        PMID: 26816887      PMCID: PMC4717752          DOI: 10.7860/JCDR/2015/15227.6951

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  16 in total

1.  In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Authors:  M de Cueto; L López; J R Hernández; C Morillo; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

Authors:  James A Karlowsky; Andrew J Denisuik; Philippe R S Lagacé-Wiens; Heather J Adam; Melanie R Baxter; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

Review 3.  The revival of fosfomycin.

Authors:  Argyris S Michalopoulos; Ioannis G Livaditis; Vassilios Gougoutas
Journal:  Int J Infect Dis       Date:  2011-09-25       Impact factor: 3.623

Review 4.  Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; Antonios G Togias; Maria Karadima; Anastasios M Kapaskelis; Petros I Rafailidis; Stavros Athanasiou
Journal:  J Antimicrob Chemother       Date:  2010-06-29       Impact factor: 5.790

Review 5.  Single-dose treatment of acute cystitis with fosfomycin tromethamine.

Authors:  G E Stein
Journal:  Ann Pharmacother       Date:  1998-02       Impact factor: 3.154

6.  Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Authors:  Elizabeth A Neuner; Jennifer Sekeres; Gerri S Hall; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

7.  Susceptibility of urinary tract bacteria to fosfomycin.

Authors:  Sofia Maraki; George Samonis; Petros I Rafailidis; Evridiki K Vouloumanou; Emmanuel Mavromanolakis; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

8.  Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.

Authors:  Rani Diana Sahni; Veeraraghavan Balaji; Rosemol Varghese; James John; Giannoula S Tansarli; Matthew E Falagas
Journal:  Future Microbiol       Date:  2013-05       Impact factor: 3.165

9.  Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer?

Authors:  Asfia Sultan; Meher Rizvi; Fatima Khan; Hiba Sami; Indu Shukla; Haris M Khan
Journal:  Urol Ann       Date:  2015 Jan-Mar

10.  Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study.

Authors:  Lu-Dong Qiao; Bo Zheng; Shan Chen; Yong Yang; Kai Zhang; Hong-Feng Guo; Bo Yang; Yuan-Jie Niu; Yi Wang; Ben-Kang Shi; Wei-Min Yang; Xiao-Kun Zhao; Xiao-Feng Gao; Ming Chen
Journal:  BMJ Open       Date:  2013-12-04       Impact factor: 2.692

View more
  4 in total

1.  Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.

Authors:  Vrushali Patwardhan; Sarman Singh
Journal:  Int Urol Nephrol       Date:  2017-06-14       Impact factor: 2.370

2.  Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia.

Authors:  Adhi Kristianto Sugianli; Franciscus Ginting; R Lia Kusumawati; Emmy Hermiyati Pranggono; Ayodhia Pitaloka Pasaribu; Firza Gronthoud; Suzanne Geerlings; Ida Parwati; Menno D De Jong; Frank Van Leth; Constance Schultsz
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

3.  Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens.

Authors:  Sayantan Banerjee; Mallika Sengupta; Tanoy Kumer Sarker
Journal:  Indian J Urol       Date:  2017 Apr-Jun

4.  Evaluation of in vitro susceptibility of fosfomycin among Enterobacteriaceae isolates from urine cultures: A study from Puducherry.

Authors:  Srirangaraj Sreenivasan; Arunava Kali; M V Pravin Charles; Seetha Kunigal
Journal:  J Lab Physicians       Date:  2019 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.